Immuneering Corporation (IMRX) vs Upstream Bio, Inc. (UPB)
Immuneering Corporation and Upstream Bio, Inc. are both Biotechnology companies. Immuneering Corporation and Upstream Bio, Inc. are of similar size ($283.2M and $280.8M). Upstream Bio, Inc. grew revenue faster over the last twelve months: 16.0% against −84.8%. Immuneering Corporation has the higher net margin (0.00% vs −4,955.7%) and the higher return on invested capital (−97.1% vs −1,100.9%). Across the 16 metrics below, Upstream Bio, Inc. leads on 10 and Immuneering Corporation on 6.
Valuation
Profitability
| Metric | IMRX | UPB | Biotechnology median |
|---|---|---|---|
| Gross margin | 0.00% | 100.00% | 65.16% |
| Operating margin | 0.00% | (5,382.65%) | 0.00% |
| Net margin | 0.00% | (4,955.67%) | 0.00% |
| Free cash flow margin | 0.00% | (4,317.42%) | 0.00% |
| Return on equity | (52.15%) | (46.05%) | (57.72%) |
| Return on assets | (47.31%) | (44.61%) | (49.22%) |
| Return on invested capital | (97.14%) | (1,100.93%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack